Clone:
REAL912
Type of antibody:
Releasable fluorochromes, Primary antibodies, Recombinant antibodies
Applications:
MICS, IHC, IF
Alternative names:
Collagen 3, COL3A1

Specifications for Collagen III Antibody, anti-human, REAdye_lease™

Overview

Clone REA912 is an antibody fragment derived from the full Collagen III antibody molecule. It displays no binding to Fc receptors. The recombinantly engineered antibody fragments are multimerized to form the REAdye_lease Complex to bind markers with high avidity.
Clone REAL912 recognizes Collagen III, a fibrillar scleroprotein, is encoded by the COL3A1 gene. Collagen III consists of only one α collagen chain which forms a homotrimer containing three α1(III) chains and is secreted by fibroblasts and other mesenchymal cell types. It occurs in most extensible connective tissues e.g. in skin, lung, in the vascular system and in bone, cartilage, dentin, tendon, bone marrow and stroma. Collagen III is associated with type I collagen, which are the major components of the interstitial matrix. Collagen III plays a role in the regulation of cortical development. Genomic mutations of COL3A1 lead to different types of Ehlers-Danlos syndrome or aortic aneurysm abdominal (AAA).
For removal of REAdye_lease fluorochromes for optional relabeling with different fluorochrome-conjugated REAdye_lease antibodies use the REAlease Support Kit (130-120-675)

Alternative names

Collagen 3, COL3A1

Detailed product information

Technical specifications

CloneREAL912
Clonalitymonoclonal
Isotype controlControl Antibody
Hostcell line
Type of antibodyReleasable fluorochromes, Primary antibodies, Recombinant antibodies
Specieshuman
AntigenCollagen III
Alternative names of antigenCollagen 3, COL3A1
Distribution of antigenfibroblasts, mesenchymal stem cells, skin, lung, bone, bone marrow

References for Collagen III Antibody, anti-human, REAdye_lease™

Publications

  1. Fleischmajer, R. et al. (1990) Type I and type III collagen interactions during fibrillogenesis. Ann. N. Y. Acad. Sci. 580: 161-175
  2. Engqvist, H. et al. (2019) Immunohistochemical validation of COL3A1, GPR158 and PITHD1 as prognostic biomarkers in early-stage ovarian carcinomas. BMC Cancer 19(1): 928
  3. Ghali, N. et al. (2019) Atypical COL3A1 variants (glutamic acid to lysine) cause vascular Ehlers-Danlos syndrome with a consistent phenotype of tissue fragility and skin hyperextensibility. Genet. Med. 21(9): 2081-2091